Good laboratory practice - The why and the how

Good Laboratory Practice - The Why and the How

Volumn , Issue , 2005, Pages 1-424

  Seiler, Jürg P ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84920093173     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-28234-3     Document Type: Book

References (52)

1. Beernaert, H, Caroli, S, Clausing, P, Doherty, B, Edelmann, A, Hede, R, Helder, Th, Lange, J, Lehn, H, McCormack, J, Seiler, JP, Turnheim, D (2000), The Revised Principles of Good Laboratory Practice of the Organisation for Economic Cooperation and Development - Changes, Chances, and Controversies, Drug Information Journal 34(1), pp. 33-45
2. Berny, C, and Long, D (1989), Quality Assurance Impact: Can It Be Measured?, J. Amer. Coll. Toxicol. 8(2), pp. 419-428.
3. Clausen, T, and Riius, P (1997), Simple guidelines for experimental reports, documentation and storage of data. A new initiative to further research integrity, Dan. Med. Bull. 44 (1) pp. 85-87.
4. Committee on Public Labor and Welfare (1975), Preclinical and Clinical Testing by the Pharmaceutical Industry 1975, Joint Hearings before the Subcommittee on Health of the Committee on Labor and Public Welfare and the Subcommittee on Administrative Practice and Procedure of the Committee on the Judiciary. United States Senate, Ninetyfourth Congress. First Session on Examination of the process of drug testing and FDA's role in the regulation and conditions under which such testing is carried out, July 10 and 11, 1975.
5. Coombes, P (2000), The Future of Electronic Signatures, Pharm. Tech. Europe 12(4), pp. 24-26.
6. Cooper-Hannan, R, Harbell, JW, Coecke, S, Balls, M, Bowe, G, Cervinka, M, Clothier, R, Hermann, F, Klahm, LK, De Lange, J, Liebsch, M, and Vanparys, Ph (1999), The Principles of Good Laboratory Practice: Application to In Vitro Toxicology Studies, ATLA 27, pp. 539-577.
7. CPMP (2001), Note for Guidance on the investigation of bioavailability and bioequivalence, London, CPMP/EWP/QWP/1401/98
8. CPMP (2004), Guideline on the evaluation of control samples for toxicokinetics parameters in toxicology studies: checking for contamination with the test substance, Draft, London, EMEA/CPMP/SWP/1094/04/corr
9. CWIS (2000), L1 - Good Laboratory Practice, Liverpool John Moores University, Campus Wide Information Service, Health and Safety Unit, Laboratory and Workshop Safety Notes (www.cwis.livjm.ac.uk/hse)
10. Dalton, R (1999), Roche's Taq patent "obtained by deceit", rules US court, Nature (news) 402, 16 December, p. 709.
11. Dent, NJ (1994), GLP Compliance in the European Clinical Laboratory, Appl. Clin. Trials 3(4), 44-54.
12. DHHS (1992), Guidelines for the Conduct of Research Within the Public Health Service, US Department of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Health, January 1 1992.
13. EPA (1995), Good Automated Laboratory Practices, Office of Information Resources Management, Research Triangle Park, NC 27711
14. FDA (2003 a), Guidance for Industry, Part 11, Electronic Records; Electronic Signatures - Scope and Application, US Department of Health and Human Services, Food and Drug Administration, August 2003
15. FDA (2003 b), Guidance for Industry, Pharmacogenomic Data Submissions, US Department of Health and Human Services, Food and Drug Administration, November 2003
16. Finney, DJ (2000), Symbols and Terminology in Biometry, Biometrical Journal 42(1), pp. 5-16.
17. Fox, M, Bloom, JC, Conolly, MM, and De Risi, MF (1995), Picking a Centralized Laboratory, Appl. Clin. Trials, Supplement 1, p. 13.
18. Goodman, B (1996), Decision In Imanishi-Kari Appeal Spurs Call for Changes In System, The Scientist, 10(16), pp. 1 and 6-7.
19. Homberger, FR, Boot, R, Feinstein, R, Kornerup-Hansen, A, and Van Der Logt, J (1999), FELASA guidance paper for the accreditation of animal diagnostic laboratories, Lab. Animals 33(Suppl. 1), pp. 19-38.
20. Humphrey, GF (1994), Scientific Fraud: The McBride Case - Judgment, Med. Sci. Law 34(4), pp. 299-306.
21. ICH (1994), Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies, International Conference on Harmonization, Guideline S3A
22. ICH (1996), Guideline for Good Clinical Practice - Consolidated Guideline, International Conference on Harmonization, Guideline E6
23. ICH (2000), Safety Pharmacology Studies for Human Pharmaceuticals, International Conference on Harmonization, Guideline S7A
24. Lane, R (1997), Software Validation in the Pharmaceutical Industry - A Supplier's View, Pharm. Tech. Europe 9(2), pp. 36-37.
25. Law, J (1999), Fighting fraud in clinical trials, Scrip Magazine, September 1999, pp. 33-37.
26. OAML (1997), Ontario Association of Medical Laboratories Guideline for Clinical Laboratory Practice, CLP014, Guidelines for the Laboratory Monitoring of Oral Anticoagulants
27. OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring
28. Number 1: OECD Principles on Good Laboratory Practice (as Revised in 1997), Paris 1998
29. Number 2 (Revised): Guidance for GLP Monitoring Authorities, Revised Guides for Compliance Monitoring Procedures for Good Laboratory Practice, Paris 1995
30. Number 3 (Revised): Guidance for GLP Monitoring Authorities, Revised Guidance for the Conduct of Laboratory Inspections and Study Audits, Paris 1995
31. Number 4 (Revised): Consensus Document, Quality Assurance and GLP, Paris 1999
32. Number 5 (Revised): Consensus Document, Compliance of Laboratory Suppliers with GLP Principles, Paris 1999
33. Number 6 (Revised): Consensus Document, The Application of the GLP Principles to Field Studies, Paris 1999
34. Number 7 (Revised): Consensus Document, The Application of the GLP Principles to Short Term Studies, Paris 1999
35. Number 8 (Revised): Consensus Document, The Role and Responsibilities of the Study Director in GLP Studies, Paris 1999
36. Number 9: Guidance for GLP Monitoring Authorities, Guidance for the Preparation of GLP Inspection Reports, Paris 1995
37. Number 10: Consensus Document, The Application of the Principles of GLP to Computerised Systems, Paris 1995
38. Number 11: Advisory Document of the Panel on Good Laboratory Practice, The Role and Responsibilities of the Sponsor in the Application of the Principles of GLP, Paris 1998
39. Number 12: Advisory Document of the Working Group on GLP, Requesting and Conducting Inspections and Audits in Another Country, Paris 2000
40. Number 13: Consensus Document, The Application of the Principles of GLP to Multi-Site Studies, Paris 2002
41. Number 14: Advisory Document of the Working Group on GLP, The Application of the Principles of GLP to in vitro Studies, Paris 2004
42. Position Paper of the OECD Panel on Good Laboratory Practice, The Use of Laboratory Accreditation with Reference to GLP Compliance Monitoring, Paris 1994
43. Reichhardt, T (1999), NASA reworks its sums after Mars fiasco, Nature 401(October 7), 517.
44. Rossiter EJR (1992), Reflections of a whistle-blower, Nature 357(June 11), pp. 434-436.
45. Schneider, K (1983), Faking It - The Case Against Industrial Bio-Test Laboratories, The Amicus Journal, Spring 1983, pp. 14-26.
46. Segalstad, SH (1996), Supplier Auditing and Software, Eur. Pharm. Review, September, pp. 37-44.
47. Stokes, T (1999), Computer Validation in the Regulated Laboratory, Pharm. Tech. Europe 11(12), pp. 16-24.
48. TDR (2001), Handbook - Good Laboratory Practice (GLP), UNDP/World Bank/WHO/TDR, Geneva
49. TDR (2001), Training Manual - Good Laboratory Practice (GLP), UNDP/World Bank/WHO/TDR, Geneva
50. Toronto Medical Laboratories (2003), Laboratory Safety Manual, Good Laboratory Practice - Summary, p. 18 (http://microbiology.mtsinai.on. ca/manual/ls/ls05.pdf)
51. UK (1989), The application of GLP Principles to computer systems (Advisory Leaflet number 1), UK GLP Compliance Programme, Department of Health, London.
52. Weiss, RB, Rifkin, RM, Stewart, FM, Theriault, RL, Williams, LA, Herman, AA, and Beveridge, RA (2000), High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study, The Lancet, 355(9208), pp. 999-1003.